Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CK1α activators
- Development stage
- Preclinical
- Lead developer
- StemSynergy Therapeutics
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Local
01
Overview
CK1α activators are a class of small molecule therapeutics being developed by StemSynergy Therapeutics to treat colorectal and other Wnt-driven cancers. These compounds function by activating Casein Kinase 1 alpha (CK1α), a key negative regulator of the Wnt/β-catenin signaling pathway. By enhancing CK1α activity, these activators promote the phosphorylation and subsequent degradation of β-catenin, thereby suppressing the aberrant Wnt signaling that drives tumor growth and survival in specific oncogenic contexts. The program is currently in the IND-enabling phase of development.
- Other names
- CK1α activators
02
Targets
CK1α (Casein kinase I alpha)
Beyond the preview
Go deeper on CK1α activators.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CK1α activators.